Expanding Access

Towards true affordability

Currently only 8% of an eligible 75 million patients are treated with Biologics globally. Cipla BioTec aims to address this with low and relevant pricing that makes the drug truly affordable to the masses.

It is estimated that by the year 2025, patients treated with Biologics who would be suffering from major cancers would be 3 times larger compared to ~0.5 million people being treated today. Cipla BioTec aspires to treat 1 in every 3 eligible cancer patients in developing markets with our pipeline products. Technology that will drive higher efficiency and Cipla’s supporting infrastructure that will result in fast penetration into public health systems will aid in our access expansion strategy.

Current Biologic Penetration Rate

 
 

*Indications considered:
Cancers of Colorectum, Kidney, Lung, Breast, H&N, Glioblastoma, Rheumatoid Arthritis, Severe Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn’s Disease, Ulcerative colitis, Juvenile Idiopathic Arthritis

Sources:
Industry interviews; internal analysis